D57.01 Insurance Policy Changes

ICD-10 D57.01 is officially defined as "Hb-SS disease with acute chest syndrome." code D57.01 is referenced in 4 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D57.01 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Allogeneic hematopoietic cell transplantation is considered medically necessary for select patients with sickle cell anemia (children or young adults with a prior stroke or an increased risk of stroke or end-organ damage), homozygous beta-thalassemia, aplastic anemia (hereditary or acquired), certain primary immunodeficiencies, lysosomal and peroxisomal storage disorders except Hunter, Sanfilippo, and Morquio syndromes, and infantile malignant osteopetrosis. No benefits are provided for a covered transplant procedure or a transplant evaluation unless the member receives prior authorization through case management from Blue Cross & Blue Shield of Mississippi.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with no substantive changes to coverage criteria. The policy continues to cover this gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity requirements. No billing or documentation workflow changes are required.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
This is a reissue of Independence Blue Cross policy 08.02.14a with no substantive changes to coverage criteria for Casgevy (exagamglogene autotemcel), a gene therapy for severe sickle cell disease and transfusion-dependent β-thalassemia in patients 12 years and older. The policy maintains existing medical necessity requirements, including prior treatment attempts, documented severe vaso-occlusive crises, and eligibility criteria. Billing teams should verify this reissue does not affect current claim processing but confirm HCPCS code J3392 remains the appropriate billing code.
Independence Blue Cross · Effective Jul 1, 2025Low impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross reissued Policy 08.02.14a for Casgevy (exagamglogene autotemcel) with NO CONTENT CHANGES on 07/01/2025. This is an informational reissue confirming continued coverage for severe sickle cell disease and transfusion-dependent β-thalassemia in patients aged 12+ who meet strict medical necessity criteria. No billing workflow changes are required.

Watch D57.01

Get one email when a payer policy names D57.01, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code D57.01?

There are 4 tracked policy changes affecting code D57.01, including updates from Blue Cross & Blue Shield of Mississippi, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D57.01?

Payers that have issued tracked updates for code D57.01 include: Blue Cross & Blue Shield of Mississippi, Independence Blue Cross.

How do I get notified when code D57.01 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D57.01. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D57.01?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias

08.02.14a, Casgevy™ (exagamglogene autotemcel)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

08.02.14a, Casgevy™ (exagamglogene autotemcel)

What insurance policy changes affect code D57.01?

Which payers have updated policy for code D57.01?

How do I get notified when code D57.01 policy changes?

Why do payers change policies for code D57.01?